Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

188 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of a pediatric-inspired treatment protocol versus standard-intensity chemotherapy for young adults with standard-risk BCR-ABL negative acute lymphoblastic leukemia.
Kliman D, Barnett M, Broady R, Forrest D, Gerrie A, Hogge D, Nantel S, Narayanan S, Nevill T, Power M, Sanford D, Song K, Sutherland H, Toze C, Abou Mourad Y. Kliman D, et al. Leuk Lymphoma. 2017 Apr;58(4):909-915. doi: 10.1080/10428194.2016.1222376. Epub 2016 Aug 26. Leuk Lymphoma. 2017. PMID: 27561638
Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels.
Forrest DL, Trainor S, Brinkman RR, Barnett MJ, Hogge DE, Nevill TJ, Shepherd JD, Nantel SH, Toze CL, Sutherland HJ, Song KW, Lavoie JC, Power MM, Abou-Mourad Y, Smith CA. Forrest DL, et al. Among authors: hogge de. Leuk Res. 2009 Feb;33(2):271-5. doi: 10.1016/j.leukres.2008.07.015. Epub 2008 Aug 31. Leuk Res. 2009. PMID: 18762338
IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.
Nevill TJ, Shepherd JD, Sutherland HJ, Abou Mourad YR, Lavoie JC, Barnett MJ, Nantel SH, Toze CL, Hogge DE, Forrest DL, Song KW, Power MM, Nitta JY, Dai Y, Smith CA. Nevill TJ, et al. Among authors: hogge de. Biol Blood Marrow Transplant. 2009 Feb;15(2):205-13. doi: 10.1016/j.bbmt.2008.11.015. Biol Blood Marrow Transplant. 2009. PMID: 19167680 Free article.
Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months).
Venner CP, Connors JM, Sutherland HJ, Shepherd JD, Hamata L, Mourad YA, Barnett MJ, Broady R, Forrest DL, Hogge DE, Nantel SH, Narayanan S, Nevill TJ, Nitta J, Power MM, Toze CL, Smith CA, Song KW. Venner CP, et al. Among authors: hogge de. Leuk Lymphoma. 2011 Jan;52(1):34-41. doi: 10.3109/10428194.2010.531409. Epub 2010 Dec 6. Leuk Lymphoma. 2011. PMID: 21133716
Long-term follow-up of patients with chronic myeloid leukemia in chronic phase developing sudden blast phase on imatinib therapy.
Tantiworawit A, Power MM, Barnett MJ, Hogge DE, Nantel SH, Nevill TJ, Shepherd JD, Song KW, Sutherland HJ, Toze CL, Abou-Mourad YR, Narayanan S, Broady RC, Forrest DL. Tantiworawit A, et al. Among authors: hogge de. Leuk Lymphoma. 2012 Jul;53(7):1321-6. doi: 10.3109/10428194.2011.652108. Epub 2012 Mar 5. Leuk Lymphoma. 2012. PMID: 22192245
Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation.
Sun H, Savage KJ, Karsan A, Slack GW, Gascoyne RD, Toze CL, Sehn LH, Abou Mourad Y, Barnett MJ, Broady RC, Connors JM, Forrest DL, Gerrie AS, Hogge DE, Narayanan S, Nevill TJ, Nantel SH, Power MM, Sutherland HJ, Villa D, Shepherd JD, Song KW. Sun H, et al. Among authors: hogge de. Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):341-8. doi: 10.1016/j.clml.2014.12.015. Epub 2015 Jan 3. Clin Lymphoma Myeloma Leuk. 2015. PMID: 25656914
Outcomes of Intermediate Risk Karyotype Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared With Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-score Adjusted Analysis.
Limvorapitak W, Barnett MJ, Hogge DE, Forrest DL, Nevill TJ, Narayanan S, Power MM, Nantel SH, Broady R, Song KW, Toze CL, Mourad YA, Sutherland HJ, Gerrie AS, White J, Sanford DS. Limvorapitak W, et al. Among authors: hogge de. Clin Lymphoma Myeloma Leuk. 2018 Nov;18(11):e481-e491. doi: 10.1016/j.clml.2018.07.290. Epub 2018 Jul 17. Clin Lymphoma Myeloma Leuk. 2018. PMID: 30100330 Clinical Trial.
Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission.
Chalandon Y, Barnett MJ, Horsman DE, Conneally EA, Nantel SH, Nevill TJ, Nitta J, Shepherd JD, Sutherland HJ, Toze CL, Hogge DE. Chalandon Y, et al. Among authors: hogge de. Biol Blood Marrow Transplant. 2002;8(8):435-43. doi: 10.1053/bbmt.2002.v8.pm12234169. Biol Blood Marrow Transplant. 2002. PMID: 12234169 Free article.
188 results